Matthew Norton, DO
Internal Medicine · South Bend, INNPI 1205064870
Payments from drug & device makers
Across 162 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$556
- Novo Nordisk$526
- Lilly USA, LLC$356
- AstraZeneca$227
- Boehringer Ingelheim$222
- Amgen$218
- plus $907 from 25 others
What the payments were for
- Food & beverage$3,012100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $556 |
| Novo Nordisk | 24 | $526 |
| Lilly USA, LLC | 21 | $356 |
| AstraZeneca | 12 | $227 |
| Boehringer Ingelheim | 12 | $222 |
| Amgen | 14 | $218 |
| Abbott | 6 | $108 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Exact Sciences | 6 | $86 |
| Pfizer | 4 | $65 |
| Lundbeck LLC | 3 | $62 |
| Dexcom, Inc. | 3 | $46 |
| GSK | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Insulet Corporation | 2 | $35 |
| Edwards Lifesciences | 1 | $35 |
| IBSA Pharma Inc. | 2 | $31 |
| RGH Enterprises LLC | 1 | $28 |
| Genentech USA, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $20 |
| Merck | 1 | $19 |
| VBI Vaccine (delaware) Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Bayer | 1 | $17 |
| Terumo Medical Corporation | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$119
How this compares
$3,012 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $136,401 |
| OzempicSemaglutide | 41 | $51,611 |
| FarxigaDapagliflozin Propanediol | 41 | $43,803 |
| JanuviaSitagliptin Phosphate | 28 | $29,748 |
| EliquisApixaban | 21 | $22,041 |
| MounjaroTirzepatide | 16 | $18,672 |
| TrulicityDulaglutide | 16 | $17,147 |
| MyrbetriqMirabegron | 12 | $8,379 |
| Fenofibrate | 13 | $4,761 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,130 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,788 |
| Atorvastatin Calcium | 243 | $1,348 |
| Ezetimibe | 47 | $1,080 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,066 |
| Levothyroxine Sodium | 122 | $920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $222 | $136,401112 claims |
| Novo NordiskOzempic | $526 | $51,61141 claims |
| AstraZenecaFarxiga | $227 | $43,80341 claims |
| Lilly USA, LLCMounjaro, Trulicity | $356 | $35,81932 claims |
| MerckJanuvia | $19 | $29,74828 claims |
| PfizerEliquis | $65 | $22,04121 claims |
| GSKBreo Ellipta | $45 | $4,13011 claims |
| AbbVieSynthroid | $556 | $80119 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $29554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in South Bend
- Rita SchmidSouth Bend$599K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.